Contineum Therapeutics, Inc. (CTNM) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 12/31/25
Wall Street Analysts See a 91.49% Upside in Contineum Therapeutics, Inc. (CTNM): Can the Stock Really Move This High?Zacks Investment Research • 12/31/25
Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public OfferingBusiness Wire • 12/12/25
Contineum Therapeutics to Attend the 8th Annual Evercore Healthcare ConferenceBusiness Wire • 11/24/25
Contineum Therapeutics' Multiple Sclerosis Trial Disappoints, But Analyst Sees Other Assets Driving ValueBenzinga • 11/21/25
Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)Business Wire • 11/20/25
Contineum Therapeutics Reports Third-Quarter 2025 Financial Results; Affirms Key Clinical Development MilestonesBusiness Wire • 10/30/25
Contineum Therapeutics Reports Positive Topline Data From Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791Business Wire • 09/18/25
Wall Street Analysts Think Contineum Therapeutics, Inc. (CTNM) Could Surge 235.81%: Read This Before Placing a BetZacks Investment Research • 08/08/25
Contineum Therapeutics Reports Second-Quarter 2025 Financial Results; Updates Key Clinical Development MilestonesBusiness Wire • 08/05/25
Contineum Therapeutics Provides Update on Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791Business Wire • 06/25/25
Contineum Therapeutics to Present at the 2025 RBC Capital Markets Global Healthcare ConferenceBusiness Wire • 05/15/25
Contineum Therapeutics Reports First-Quarter 2025 Financial Results; Affirms Key Clinical Development MilestonesBusiness Wire • 05/14/25
Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of DevelopmentBusiness Wire • 04/28/25
Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of DirectorsBusiness Wire • 03/17/25
Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development MilestonesBusiness Wire • 03/06/25
Contineum Therapeutics Initiates Patient Dosing in Phase 1b Chronic Pain Trial of PIPE-791Business Wire • 03/04/25
Contineum Therapeutics to Present at the 2025 Leerink Partners Global Healthcare ConferenceBusiness Wire • 03/03/25
Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)Business Wire • 01/08/25
Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791Business Wire • 12/16/24
Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx ConferenceBusiness Wire • 11/25/24